{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:50:33Z","timestamp":1778867433088,"version":"3.51.4"},"reference-count":72,"publisher":"Elsevier BV","issue":"51","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.vaccine.2016.02.015","type":"journal-article","created":{"date-parts":[[2016,6,15]],"date-time":"2016-06-15T20:26:00Z","timestamp":1466022360000},"page":"6617-6625","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Adventitious agents and live viral vectored vaccines: Considerations for archiving samples of biological materials for retrospective analysis"],"prefix":"10.1016","volume":"34","author":[{"given":"Bettina","family":"Klug","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James S.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard C.","family":"Condit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Seligman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marian P.","family":"Laderoute","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Sheets","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna-Lise","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Gurwith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonali","family":"Kochhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louisa","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baevin","family":"Carbery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa M.","family":"Mac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.02.015_bib0005","first-page":"243","article-title":"Impact of vaccines universally recommended for children \u2013 United States, 1990\u20131998","volume":"48","author":"Centers for Disease Control and Prevention","year":"1999","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0010","series-title":"Smallpox and its eradication","author":"Fenner","year":"1988"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0015","first-page":"353","article-title":"Progress toward interruption of wild poliovirus transmission \u2013 worldwide, January 2011\u2013March 2012","volume":"61","author":"Centers for Disease Control and Prevention","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"Suppl 4","key":"10.1016\/j.vaccine.2016.02.015_bib0020","doi-asserted-by":"crossref","first-page":"D91","DOI":"10.1016\/j.vaccine.2011.04.059","article-title":"Measles and rubella eradication in the Americas","volume":"29","author":"Andrus","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0025","unstructured":"World Health Organization. Annex 3. Recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterization of cell banks. WHO Technical Report Series, No 9782010."},{"key":"10.1016\/j.vaccine.2016.02.015_bib0030","first-page":"153","article-title":"Detection of adventitious viruses in biologicals\u2014a rare occurrence","volume":"123","author":"Nims","year":"2006","journal-title":"Dev Biol"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0035","unstructured":"The International Conference on Harmonisation (ICH) guidance Q5A: viral safety evaluation of biotechnology products derived from cell lines of human or animal origin (63 FR 51074; September 24, 1998)."},{"key":"10.1016\/j.vaccine.2016.02.015_bib0040","doi-asserted-by":"crossref","first-page":"6033","DOI":"10.1128\/JVI.02690-09","article-title":"Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus","volume":"84","author":"Victoria","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0045","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1399-3089.2004.00134.x","article-title":"Infection studies on human cell lines with porcine circovirus type 1 and porcine circovirus type 2","volume":"11","author":"Hattermann","year":"2004","journal-title":"Xenotransplantation"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0050","doi-asserted-by":"crossref","DOI":"10.4161\/hv.25973","article-title":"Investigation of a regulatory agency enquiry into potential porcine circovirus type 1 contamination of the human rotavirus vaccine, Rotarix: approach and outcome","volume":"9","author":"Dubin","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0055","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1353\/pbm.0.0010","article-title":"The first pharmacoepidemiologic investigations: national drug safety policy in the United States, 1901\u20131902","volume":"51","author":"Lilienfeld","year":"2008","journal-title":"Perspect Biol Med"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0060","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.biologicals.2014.07.003","article-title":"Adventitious agents in viral vaccines: lessons learned from 4 case studies","volume":"42","author":"Petricciani","year":"2014","journal-title":"Biologicals: J Int Assoc Biol Stand"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0065","first-page":"48","article-title":"Progress in immunization information systems\u2014United States, 2011","volume":"62","author":"Centers for Disease Control and Prevention","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0070","series-title":"Transmissible spongiform encephalopathies advisory committee vaccines and related biological producers advisory committee","author":"U.S. Food and Drug Administration","year":"2000"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0075","series-title":"Immunization safety review: SV40 contamination of polio vaccine and cancer","author":"Stratton","year":"2003"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0080","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.vaccine.2014.09.035","article-title":"The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG)","volume":"33","author":"Chen","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0085","article-title":"Lessons learned in shaping vaccine markets in low-income countries: a review of the vaccine market segment supported by the GAVI Alliance","author":"Gilchrist","year":"2012","journal-title":"Health Policy Plan"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0090","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1586\/erv.09.23","article-title":"Reaching international GMP standards for vaccine production: challenges for developing countries","volume":"8","author":"Milstien","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0095","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1016\/j.vaccine.2012.05.045","article-title":"Capacity for a global vaccine safety system: the perspective of national regulatory authorities","volume":"30","author":"Graham","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0100","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.biologicals.2011.08.003","article-title":"Evaluation of the human host range of bovine and porcine viruses that may contaminate bovine serum and porcine trypsin used in the manufacture of biological products","volume":"39","author":"Marcus-Sekura","year":"2011","journal-title":"Biologicals: J Int Assoc Biol Stand"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0105","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.biologicals.2010.01.013","article-title":"Viral safety and extraneous agents testing for veterinary vaccines","volume":"38","author":"Dodet","year":"2010","journal-title":"Biologicals: J Int Assoc Biol Stand"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0110","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.semcancer.2009.03.001","article-title":"Polyoma virus and simian virus 40 as cancer models: history and perspectives","volume":"19","author":"Atkin","year":"2009","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/oxfordjournals.aje.a112197","article-title":"Human exposure to SV40: review and comment","volume":"103","author":"Shah","year":"1976","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0120","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/jama.1963.03060090045016","article-title":"An evaluation of the carcinogenicity of simian virus 40 in man","volume":"185","author":"Fraumeni","year":"1963","journal-title":"JAMA: J Am Med Assoc"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/biol.1998.0170","article-title":"Examination of poliovirus vaccine preparations for SV40 sequences","volume":"27","author":"Sangar","year":"1999","journal-title":"Biologicals: J Int Assoc Biol Stand"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0130","first-page":"1","article-title":"Simian Virus 40 (SV40): a possible human polyomavirus. Symposium proceedings. Bethesda, Maryland, USA. January 27\u201328, 1997","volume":"94","year":"1998","journal-title":"Dev Biol Stand"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0135","first-page":"61","article-title":"Forty-ninth report: 1990 requirements for poliomyelitis vaccine (oral) (addendum, 1998)","volume":"897","author":"WHO Expert Committee on Biological Standardization","year":"2000","journal-title":"World Health Organ Tech Rep Ser"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0140","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/nrc947","article-title":"SV40 and human tumours: myth, association or causality?","volume":"2","author":"Gazdar","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0145","doi-asserted-by":"crossref","first-page":"10273","DOI":"10.1158\/0008-5472.CAN-05-2028","article-title":"Some oral poliovirus vaccines were contaminated with infectious SV40 after 1961","volume":"65","author":"Cutrone","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0150","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1586\/ers.11.51","article-title":"Simian virus 40 transformation, malignant mesothelioma and brain tumors","volume":"5","author":"Qi","year":"2011","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0155","unstructured":"World Health Organization. Recommendations for the production and control of poliomyelitis vaccine (inactivated). WHO Technical Report Series, No 9102002."},{"key":"10.1016\/j.vaccine.2016.02.015_bib0160","series-title":"Code of Federal Regulations Title 21","author":"U.S. Food and Drug Administration","year":"2011"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0165","series-title":"Guidelines to good manufacturing practice medicinal products for human and veterinary use: annex 19 reference and retention samples. Brussels","author":"European Commission","year":"2005"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0170","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1600-0463.2009.02452.x","article-title":"Tumour virology \u2014 history, status and future challenges","volume":"117","author":"Kalland","year":"2009","journal-title":"APMIS: acta pathologica, microbiologica, et immunologica Scandinavica"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0175","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1586\/14760584.4.4.553","article-title":"Yellow fever vaccine","volume":"4","author":"Monath","year":"2005","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0180","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1126\/science.177.4043.76","article-title":"Yellow fever vaccination, avian leukosis virus, and cancer risk in man","volume":"177","author":"Waters","year":"1972","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0185","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1128\/JVI.77.2.1105-1111.2003","article-title":"Identification and characterization of avian retroviruses in chicken embryo-derived yellow fever vaccines: investigation of transmission to vaccine recipients","volume":"77","author":"Hussain","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0190","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/hep.1840180407","article-title":"Mortality follow-up of the 1942 epidemic of hepatitis B in the U.S. Army","volume":"18","author":"Norman","year":"1993","journal-title":"Hepatol"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0195","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1056\/NEJM198704163161601","article-title":"A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army","volume":"316","author":"Seeff","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0200","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.1128\/JVI.73.7.5843-5851.1999","article-title":"Evidence of avian leukosis virus subgroup E and endogenous avian virus in measles and mumps vaccines derived from chicken cells: investigation of transmission to vaccine recipients","volume":"73","author":"Tsang","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0205","doi-asserted-by":"crossref","first-page":"8236","DOI":"10.1016\/j.vaccine.2010.10.070","article-title":"WHO Working Group on technical specifications for manufacture and evaluation of yellow fever vaccines, Geneva, Switzerland, 13\u201314 May 2009","volume":"28","author":"Ferguson","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0210","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1006\/biol.1997.0111","article-title":"Assessing the significance of the presence of RTase in live viral vaccines","volume":"25","author":"Robertson","year":"1997","journal-title":"Biologicals: J Int Assoc Biol Stand"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0215","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0928-0197(95)00159-X","article-title":"Detection of reverse transcriptase activity in live attenuated virus vaccines","volume":"5","author":"Boni","year":"1996","journal-title":"Clin Diagn Virol"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0220","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1128\/JCM.39.2.675-684.2001","article-title":"No evidence of infectious retroviruses in measles virus vaccines produced in chicken embryo cell cultures","volume":"39","author":"Shahabuddin","year":"2001","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0225","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0928-0197(98)00042-7","article-title":"The reverse transcriptase activity in cell-free medium of chicken embryo fibroblast cultures is not associated with a replication-competent retrovirus","volume":"11","author":"Khan","year":"1998","journal-title":"J Clin Virol: Off Publ Pan Am Soc Clin Virol"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0230","first-page":"209","article-title":"Reverse transcriptase activity in chicken-cell derived vaccine","volume":"73","year":"1998","journal-title":"Releve epidemiologique hebdomadaire\/Section d\u2019hygiene du Secretariat de la Societe des Nations=Weekly epidemiological record\/Health Section of the Secretariat of the League of Nations"},{"issue":"Pt 9","key":"10.1016\/j.vaccine.2016.02.015_bib0235","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1099\/0022-1317-79-9-2171","article-title":"Characterization of novel circovirus DNAs associated with wasting syndromes in pigs","volume":"79","author":"Meehan","year":"1998","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0240","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1016\/j.vaccine.2011.04.087","article-title":"Molecular and infectivity studies of porcine circovirus in vaccines","volume":"29","author":"McClenahan","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0245","unstructured":"U.S. Food and Drug Administration. Code of Federal Regulations Title 9. 2012. 9 CRF 113.53 Requirements for ingredients of animal origin used for production of biologics."},{"key":"10.1016\/j.vaccine.2016.02.015_bib0250","unstructured":"U.S. Food and Drug Administration. Code of Federal Regulations Title 19 CFR 113.47 Detection of extraneous viruses by the fluorescent antibody technique."},{"key":"10.1016\/j.vaccine.2016.02.015_bib0255","first-page":"17","article-title":"Some biological and physico-chemical properties of porcine circovirus","volume":"41","author":"Allan","year":"1994","journal-title":"Zentralbl Vet B."},{"key":"10.1016\/j.vaccine.2016.02.015_bib0260","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/295064a0","article-title":"A very small porcine virus with circular single-stranded DNA","volume":"295","author":"Tischer","year":"1982","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0265","series-title":"Recommendation to temporarily suspend usage of GlaxoSmithKline rotarix (rotavirus) vaccine","author":"Centers for Disease Control and Prevention","year":"2010"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0270","doi-asserted-by":"crossref","first-page":"7303","DOI":"10.1016\/j.vaccine.2011.06.097","article-title":"Productive infection of human hepatocellular carcinoma cells by porcine circovirus type 1","volume":"29","author":"Beach","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.biologicals.2014.02.002","article-title":"Unbiased analysis by high throughput sequencing of the viral diversity in fetal bovine serum and trypsin used in cell culture","author":"Gagnieur","year":"2014","journal-title":"Biologicals: J Int Assoc Biol Stand"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0280","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.biologicals.2013.10.005","article-title":"Quantitative detection of residual porcine host cell DNA by real-time PCR","volume":"42","author":"Chang","year":"2014","journal-title":"Biologicals: J Int Assoc Biol Stand"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0285","series-title":"2.6.16. Tests for etraneous agents in viral vaccines for human use, in European Pharmacopoeia 5.0.","author":"Council of Europe","year":"2004"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0290","doi-asserted-by":"crossref","first-page":"730","DOI":"10.5731\/pdajpst.2011.00851","article-title":"Application of risk assessments in the design of the overall viral control strategy used during the manufacture and testing of live virus vaccines","volume":"65","author":"Pennathur","year":"2011","journal-title":"PDA J Pharm Sci Technol\/PDA"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0295","series-title":"Guideline on the use of porcine trypsin used in the manufacture of human biological medicinal products","author":"European Medicines Agency","year":"2014"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0300","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1086\/589624","article-title":"Anti-ganglioside antibody induction by swine (A\/NJ\/1976\/H1N1) and other influenza vaccines: insights into vaccine-associated Guillain-Barre syndrome","volume":"198","author":"Nachamkin","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0305","series-title":"Guidance for industry characterization and qualification of cell substrates and other biological materials used in the production of viral vaccines for infectious disease indications","author":"U.S. Department of Health and Human Services","year":"2010"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0310","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1128\/JVI.66.3.1590-1601.1992","article-title":"The baculovirus-integrated retrotransposon TED encodes gag and pol proteins that assemble into viruslike particles with reverse transcriptase","volume":"66","author":"Lerch","year":"1992","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0315","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1099\/vir.0.2008\/001313-0","article-title":"Integration of the reticuloendotheliosis virus envelope gene into the poultry fowlpox virus genome is not universal","volume":"89","author":"Davidson","year":"2008","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0320","first-page":"223","article-title":"Retroviral insertion into herpesviruses: discovery and implications","volume":"106","author":"Kung","year":"2001","journal-title":"Dev Biol"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0325","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1073\/pnas.89.3.991","article-title":"Retrovirus insertion into herpesvirus in vitro and in vivo","volume":"89","author":"Isfort","year":"1992","journal-title":"Proc Natl Acad Sci USA."},{"key":"10.1016\/j.vaccine.2016.02.015_bib0330","first-page":"21","article-title":"Raw materials as a source of contamination in large-scale cell culture","volume":"93","author":"Garnick","year":"1998","journal-title":"Dev Biol Stand"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0335","doi-asserted-by":"crossref","first-page":"546","DOI":"10.5731\/pdajpst.2014.01028","article-title":"Introduction and workshop summary: advanced technologies for virus detection in the evaluation of biologicals-applications and challenges","volume":"68","author":"Khan","year":"2014","journal-title":"PDA J Pharm Sci Technol\/PDA"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0340","series-title":"2012 Meeting Materials, Vaccines and Related Biological Products Advisory Committee","author":"U.S. Food and Drug Administration","year":"2012"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0345","article-title":"NYVAC-HIV vaccine applied in HVTN 092 and HVTN 096 clinical trials","author":"Vaccine News Reports","year":"2015","journal-title":"Vaccine News Daily"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0350","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.vaccine.2012.11.095","article-title":"Investigation of an outbreak of hypersensitivity-type reactions during the 2004 national measles-mumps-rubella vaccination campaign in Brazil","volume":"31","author":"Freitas","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0355","volume":"vol. 1","author":"WHO","year":"2014"},{"key":"10.1016\/j.vaccine.2016.02.015_bib0360","series-title":"Lot Distribution Database: 60081 Distribution Reports","article-title":"Guidance, Compliance & Regulatory Information (Biologics)","author":"U.S. Food and Drug Administration","year":"1994"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16001572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16001572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T16:38:53Z","timestamp":1582562333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16001572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":72,"journal-issue":{"issue":"51","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0264410X16001572"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.02.015","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adventitious agents and live viral vectored vaccines: Considerations for archiving samples of biological materials for retrospective analysis","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.02.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}